medigraphic.com

2013, Número 3

<< Anterior Siguiente >>

Rev Hosp Jua Mex 2013; 80 (3)


Leiomiomatosis uterina. Aspectos epidemiológicos, fisiopatogénicos, reproductivos, clínicos y terapéuticos

Vargas-Hernández VM, Vargas-Aguilar VM, Tovar-Rodríguez JM, Flores-Barrios K, Acosta-Altamirano G, Moreno-Eutimio MA

Idioma: Español
Referencias bibliográficas: 40
Paginas: 173-182
Archivo PDF: 323.91 Kb.


RESUMEN

Los leiomiomas uterinos son tumores benignos del músculo liso de crecimiento lento, la mayoría de las pacientes no presentan síntomas o se descubren durante una exploración ginecológica rutinaria. Las manifestaciones clínicas se presentan en 20 a 40% con hemorragia uterina anormal, dolor pélvico crónico, pesantez pélvica y ocasionalmente alteraciones reproductivas relacionadas con el tamaño y localización de los leiomiomas. El manejo médico es para mejorar la sintomatología o facilitar la cirugía, particularmente si es conservadora, evitando las complicaciones asociadas a la intervención. Los avances tecnológicos en cirugía de mínima invasión, imagenológica intervencionista, nuevos fármacos y un mejor conocimiento de la biología tumoral de los leiomiomas, han remplazado a la histerectomía como tratamiento tradicional. Los leiomiomas uterinos comúnmente se encuentran en mujeres en edad reproductiva, donde la mayoría no requiere tratamiento debido a su benignidad y sólo cuando interfiere con su calidad de vida deben tratarse de manera individual.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Laughlin SK, Schroeder JC, Baird DD. New directions in the epidemiology of uterine fibroids. Semin Reprod Med 2010; 28: 204-17.

  2. Zimmermann A, Bernuit D, Gerlinger Ch, Schaefers M, Geppert K. Prevalence, symptoms and management of uterine fibroids an international internet-based survey of 21,746 women. BMC Womens Health 2012; 12(6).

  3. Cardozo ER, Clark AD, Banks NK, Henne MB, Stegmann BJ, Segars JH. The estimated annual cost of uterine leiomyomata in the United States. Am J Obstet Gynecol 2012; 206: 211. e1-e9.

  4. Levy G, Hill MJ, Beall S, Zarek SM, Segars JH, Catherino J. Leiomyoma genetics, assisted reproduction, pregnancy and therapeutic advances. J Assist Reprod Genetics 2012; 29(8): 703-12.

  5. Sunkara SK, Khairy M, El-Toukhy T, Khalaf Y, Coomarasamy A. The effect of intramural fibroids without uterine cavity involvement on the outcome of IVF treatment: a systematic review and meta-analysis. Hum Reprod 2010; 25: 418-29.

  6. Somigliana E, De Benedictis S, Vercellini P, Nicolosi AE, Benaglia L, Scarduelli C, et al. Fibroids not encroaching the endometrial cavity and IVF success rate: a prospective study. Hum Reprod 2011; 26: 834-9.

  7. Cook H, Ezzati M, Segars JH, McCarthy K. The impact of uterine leiomyomas on reproductive outcomes. Minerva Ginecol 2010; 62: 225-36. PubMed

  8. Bosteels J, Weyers S, Puttemans P, Panayotidis C, Van Herendael B, Gomel V, et al. The effectiveness of hysteroscopy in improving pregnancy rates in subfertile women without other gynaecological symptoms: a systematic review. Hum Reprod Update 2010; 16: 1-11.

  9. Markowski DN, Helmke BM, Belge G, Nimzyk R, Bartnitzke S, Deichert U, et al. HMGA2 and p14Arf: major roles in cellular senescence of fibroids and therapeutic implications. Anticancer Res 2011; 31: 753-61.

  10. Uliana V, Marcocci E, Mucciolo M, Meloni I, Izzi C, Manno C, et al. Alport syndrome and leiomyomatosis: the first deletion extending beyond COL4A6 intron 2. Pediatr Nephrol 2011; 26: 717-24.

  11. Negrin-Perez M. Fisiopatología de la leiomiomatosis uterina. En: Vargas-Hernández VM (ed). Histerectomía indicaciones, complicaciones y alternativas. México: DEMSA; 2005, p. 231-52.

  12. Cha PC, Takahashi A, Hosono N, Low SK, Kamatani N, Kubo M, et al. A genome-wide association study identifies three loci associated with susceptibility to uterine fibroids. Nat Genet 2011; 43: 447-50.

  13. Makinen N, Mehine M, Tolvanen J, Kaasinen E, Li Y, Lehtonen HJ, et al. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 2011; 334: 252-5.

  14. Chegini N. Proinflammatory and profibrotic mediators: principal effectors of leiomyoma development as a fibrotic disorder. Semin Reprod Med 2010; 28: 180-203.

  15. Malik M, Norian J, McCarthy-Keith D, Britten J, Catherino WH. Why leiomyomas are called fibroids: the central role of extracellular matrix in symptomatic women. Semin Reprod Med 2010; 28: 169-79.

  16. Joseph DS, Malik M, Nurudeen S, Catherino WH. Myometrial cells undergo fibrotic transformation under the influence of transforming growth factor beta-3. Fertil Steril 2010; 93: 1500- 8.

  17. Laughlin SK, Herring AH, Savitz DA, Olshan AF, Fielding JR, Hartmann KE, et al. Pregnancy-related fibroid reduction. Fertil Steril 2010; 94(6): 2421-3.

  18. Yoshida S, Ohara N, XuQ, Chen W, Wang J, Nakabayashi K, et al. Cell-type specific actions of progesterona receptor modulators in the regulation of uterine leiomyoma growth. Semin Reprod Med 2010; 28: 260-73.

  19. Sánchez-Conde RM. Resonancia magnética en la patología benigna de útero y ovarios. En: Vargas-Hernández VM (ed.). Histerectomía: indicaciones, complicaciones y alternativas. México: DEMSA; 2005, p. 29-40.

  20. Shavell VI, Thakur M, Sawant A, Kruger ML, Jones TB, Singh M, et al. Adverse obstetric outcomes associated with sonographically identified large uterine fibroids. Fertil Steril 2012; 97: 107-10.

  21. Stout MJ, Odibo AO, Graseck AS, Macones GA, Crane JP, Cahill AG. Leiomyomas at routine second-trimester ultrasound examination and adverse obstetric outcomes. Obstet Gynecol 2010; 116: 1056-63.

  22. Vargas-Hernández VM, Tovar RJM, Moran VC, Moctezuma EJ. Tratamiento médico de leiomiomatosis. En: Vargas-Hernández HVM (ed.). Histerectomía: indicaciones, complicaciones y alternativas México: DEMSA; 2005, p. 315-26.

  23. Drahonovsky J, Feyereisl J. A prospective randomized comparison of vaginal hysterectomy, laparoscopically assisted vaginal hysterectomy, and total laparoscopic hysterectomy in women with benign uterine disease. Eur J Obstet Gynecol Reprod Biol 2010; 148(2): 172-6.

  24. Hinojosa CJC. Miólisis en leiomiomatosis uterina. En: Vargas-Hernández VM (ed.). Histerectomía indicaciones, complicaciones y alternativas México: DEMSA; 2005, p 309- 14.

  25. Cano-Muñoz I. Tratamiento endovascular mediante embolización. En: Vargas-Hernández VM (ed.). Histerectomía indicaciones, complicaciones y alternativas. México: DEMSA; 2005, p 295-307.

  26. Moss JG, Cooper KG, Khaund A, Murray LS, Murray GD, Wu O, et al. Randomised comparison of uterine artery embolisation (UAE) with surgical treatment in patients with symptomatic uterine fibroids (REST trial): 5-year results. BJOG 2011; 118: 936-44.

  27. Homer H, Saridogan E. Uterine artery embolization for fibroids is associated with an increased risk of miscarriage. Fertil Steril 2010; 94: 324-30.

  28. Kim HS, Baik JH, Pham LD, Jacobs MA. MR-guided highintensity focused ultrasound treatment for symptomatic uterine leiomyomata: long-term outcomes. Acad Radiol 2011; 18: 970-6.

  29. Rabinovici J, David M, Fukunishi H, Morita Y, Gostout BS, Stewart EA, et al. Pregnancy outcome after magnetic resonance-guided focused ultrasound surgery (MRgFUS) for conservative treatment of uterine fibroids. Fertil Steril 2010; 93: 199-209.

  30. LeBlang SD, Hoctor K, Steinberg FL. Leiomyoma shrinkage after MRI-guided focused ultrasound treatment: report of 80 patients. AJR Am J Roentgenol 2010; 194: 274-80.

  31. Hoellen F, Griesinger G, Bohlmann MK. Therapeutic drugs in the treatment of symptomatic uterine fibroids. Expert Opin Pharmacother 2013; 14(15): 2079-85.

  32. Croxtall JD. Ulipristal acetate: in uterine fibroids. Drugs 2012; 72: 1075-85.

  33. Feng C, Meldrum S, Fiscella K. Improved quality of life is partly explained by fewer symptoms after treatment of fibroids with mifepristone. Int J Gynaecol Obstet 2010; 109: 121-4.

  34. Esteve JL, Acosta R, Perez Y, Campos R, Hernandez AV, Texido CS. Treatment of uterine myoma with 5 or 10 mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomised clinical trial. Eur J Obstet Gynecol Reprod Biol 2012; 161: 202-8.

  35. Nieman LK, Blocker W, Nansel T, Mahoney S, Reynolds J, Blithe D, et al. Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study. Fertil Steril 2011; 95: 767-72. e1-e2.

  36. Donnez J, Tomaszewski J, Vazquez F, Bouchard P, Lemieszczuk B, Baro F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012; 366: 421-32.

  37. Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012; 366: 409-20.

  38. Parsanezhad ME, Azmoon M, Alborzi S, Rajaeefard A, Zarei A, Kazerooni T, et al. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertil Steril 2010; 93: 192-8.

  39. Ben-Sasson H, Ben-Meir A, Shushan A, Karra L, Rojansky N, Klein BY, et al. All-trans-retinoic acid mediates changes in PI3K and retinoic acid signaling proteins of leiomyomas. Fertil Steril 2011; 95: 2080-6.

  40. Zhang D, Al-Hendy M, Richard-Davis G, Montgomery-Rice V, Sharan C, Rajaratnam V, et al. Green tea extract inhibits proliferation of uterine leiomyoma cells in vitro and in nude mice. Am J Obstet Gynecol 2010; 202: 289.




2020     |     www.medigraphic.com